Industry News

Allergan plc announced today a collaboration with SonarMD ®, a leader in population health management, on the development of clinical decision support and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea in clinical practice and monitor their treatment outcomes. Moreover, the companies will establish a patient engagement platform which..."/>
Allergan Partners with SonarMD® to Develop Innovative IBS-D Patient Engagement Platform for Better Identification and Care of IBS-D Patients
CohBar, Inc., an innovative biotechnology company focused on developing mitochondria based therapeutics to treat diseases associated with aging, today announced the discovery of a large number of new biologically active peptides encoded within the genome of the mitochondria, together with the filing of 25 new provisional patent applications. The company is evaluating these..."/>
CohBar, Inc. Announces Discovery of New Peptides in the Mitochondrial Genome
CPSI Names William J. Hayes, M.D., Medical Director
Exactech, Inc., a developer and producer of bone and joint restoration products for extremities, hip, knee, and spine, announced today a successful first surgery using its new Vantage ® Total Ankle System, the newest addition to the Exactech extremities product line and its first product in the foot and ankle market. Orthopaedic surgeons Mark Easley, MD, and James Nunley, MD, of Duke University,..."/>
Exactech Breaks Ground in Foot and Ankle Market with Successful First Surgery
Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2016 financial results on November 3, 2016. Ligand’ s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call. Ligand also announced participation in the upcoming Stephens Fall Investment Conference."/>
Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference
PAREXEL International Corporation will release financial results for First Quarter Fiscal Year 2017 on Wednesday, October 26, 2016 after the close of the stock market. PAREXEL will host a conference call and live webcast at 10:00 a.m. ET on Thursday, October 27, 2016, to discuss the results. To access the webcast, visit the Investor Section of PAREXEL’ s website at"/>
PAREXEL International Announces Date of First Quarter Fiscal Year 2017 Earnings Release and Conference Call
Five Star Quality Care, Inc. commenced on October 6, 2016 by ABP Acquisition LLC, an entity controlled by Barry M. Portnoy and Adam D. Portnoy. Senior Star announced that it intends to commence a tender offer through an affiliated entity for up to 10,000,000 shares of the Company's common stock in the coming days at a..."/>
Senior Star Announces Intention to Commence Tender Offer for up to 10,000,000 Shares of Five Star Quality Care Common Stock at $3.45 Per Share in Cash
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced that its Board of Directors unanimously approved a reverse split of its common stock at a ratio of 1- for-10 and a majority voting standard for the election of directors in uncontested elections.. Reverse Stock Split As of the effective date of the reverse split, each share of issued and outstanding common stock and..."/>
Pernix Therapeutics Announces Reverse Stock Split and Corporate Governance Enhancements
Medpace has selected Montrium's eTMF Connect and RegDocs Connect solutions for the management of Medpace' clinical and regulatory documentation, improving clinical trial efficiency via a cloud-based document solution and enhancing their technology platform. Combined, these solutions form a comprehensive Electronic Document Management System. "Medpace selected Montrium after evaluating several EDMS..."/>
Medpace Selects Montrium Connect EDMS to Improve Clinical Trial Efficiency and Support its Continued Global Business Growth
BAXTER and ASPEN, show nearly 2 million U.S. hospital stays 1 involve malnutrition Malnutrition-related hospital stays have up to a five times higher risk of deaths 2, compared to patient stays not identified as malnourished Most malnourished-related hospital stays were two times longer 1 than for patient stays not identified as malnourished. DEERFIELD, Ill.---- Baxter International Inc., a global leader in PN therapy, partnered..."/>
New Data Show Malnutrition in U.S. Hospitals Associated with a $42 Billion Burden to Health System
Rennova Health, Inc., a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces that its West Palm Beach lab, Epic Reference Labs has secured a preferred provider network agreement with Community Care Plan retrospectively as of 1 ST October 2016. Under the agreement, CCP’ s more than 100,000 members in South Florida will now have access to Rennova’ s industry-leading and..."/>
Rennova Health Credentials Approved by South Florida Managed Care Organization
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the production and dispensing of high-quality innovative compounded medications, today announced events featuring its ophthalmic formulations at the annual American Academy of Ophthalmology meeting held October 15-18 in Chicago, IL. AAO, a global community of 32,000 members, is the world's largest association of eye physicians and surgeons. Mark L. Baum, CEO of Imprimis,..."/>
Imprimis Pharmaceuticals' Formulations to be Highlighted at Upcoming Annual Ophthalmology Meeting in Chicago
Kite Pharma, Inc. today announced the appointment of Chris Nowers as its Head of Europe. Nowers will be based in London. In his new role, Nowers will oversee European commercial operations to build awareness in the region of Kite’ s growing pipeline portfolio of chimeric antigen receptor and T-cell receptor therapy product candidates and prepare for the potential launch of the company’ s lead product candidate, KTE-C19."/>
Kite Pharma Appoints Chris Nowers as Head of Europe to Lead Commercial Operations and Advance the Company’s CAR/TCR Therapy Portfolio in the Region
ViewRay, Inc., makers of the world's first and only clinical MRI-guided radiation therapy system, announced today highlights from the recent 2016 Annual Meeting of the American Society for Radiation Oncology, which featured extensive clinical experience with the company's MRIdian System, as well research highlighting the MRIdian linear accelerator technology. As part of ASTRO's Scientific Sessions, 19 MRIdian clinical presentations..."/>
MRIdian Clinical Outcomes Data and Adaptive Capabilities: Highlights from ASTRO 2016
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company and its research collaborators have been invited to present data regarding the progress of VAL-083 at the following upcoming peer-reviewed scientific conferences:. European Association of NeuroOncology Annual Meeting; AACR DNA..."/>
DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations
Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, today announces that Jarrod Longcor, senior vice president of corporate development and operations, will present at the BIO Investor Forum in San Francisco on October 18, 2016.. The company’ s presentation at the BIO Investor Forum will be held at 1:30 PM PT in the Elizabethan B Room of the Westin St. Francis on 335 Powell Street in San Francisco, CA."/>
Cellectar Biosciences To Present at BIO Investor Forum
Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, will ring the Closing Bell at Nasdaq today in celebration of its recently closed $30 million financing. Histogenics President and CEO, Adam Gridley will be joined by the Company’ s executive team and colleagues for the Closing Bell ceremony beginning at 3:45 pm ET.. A livestream of the Nasdaq Closing Bell will be..."/>
Histogenics Corporation to Ring the Nasdaq Stock Market Closing Bell
Akorn, Inc., a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, November 3, 2016 outlining the third quarter 2016 results.. In addition, the Company will host a conference call at 10:00 am EDT on the same day to discuss its third quarter 2016 financial results. The dial-in number to access the call is 249-9382 in the U.S. and +1 823-1530 for international callers."/>
Akorn Announces Third Quarter 2016 Earnings Release and Conference Call Information
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the acceptance of four abstracts for presentation at the 55 th Annual Meeting of the American College of Neuropsychopharmacology, December 4-8, 2016, at the Diplomat Hotel in Hollywood, Florida.. Highlighting these is the abstract,“ Efficacy and Safety of MIN-101: A New Drug for..."/>
Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting
WellCare Health Plans, Inc. announced today that it named Elizabeth Miller state president, Florida, effective Oct. 15. She will have responsibility for WellCare's Medicaid and Medicare Advantage businesses across the state, including strategy, regulatory compliance, network management, sales and marketing, medical management, finance and administration. Miller will report to Gregg MacDonald, who has taken a broader role at WellCare as a..."/>
WellCare Names Elizabeth Miller State President, Florida
Cerus Corporation announced today that The Community Blood Center of Appleton, Wisconsin has submitted the first Biologics License Application to the U.S. Food and Drug Administration requesting allowance for interstate distribution of platelets that have been pathogen-reduced via the INTERCEPT Blood System. “We look forward to the FDA’ s review of our application, and our ability to supply INTERCEPT-treated platelets to hospital customers outside of..."/>
Cerus Announces First U.S. Blood Center Customer Submits Biologics License Application to the FDA to Allow for Interstate Export of INTERCEPT Platelet Components
SIGA Technologies, Inc. today announced that Dr. Phil Gomez has been appointed the company’ s new Chief Executive Officer. Eric Rose will become Executive Chairman of the Board of Directors."/>
SIGA Announces Dr. Phil Gomez Joins Company as New CEO, Dr. Eric Rose to Serve as Executive Chairman of the Board

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology797 Articles
Consumer Discretionary706 Articles
Financials691 Articles
Industrials541 Articles
Health Care516 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at